What can be included in the database?
The database may include a substance or product that has proven efficacy in the primary and secondary prevention of proxy diseases of aging and in enhancing the associated adaptive mechanisms.
Methodology
Based on the submitted materials, as well as the available global evidence base, an international expert commission identifies the targeting of a substance (product, technology) in relation to specific proxy diseases of aging.
Proresilients statuses
Proresilients are substances and products that help enhance adaptation to age-related changes and diseases.
-
Proresilient is a substance or product that enhances the body's adaptability, supports physiological resilience, and helps mitigate the impact of age-related (proxy) diseases.
-
Candidate into proresilient is a substance or a product that shows potential proresilient properties based on preliminary studies or available data, but requires further validation.
-
Under consideration - a substance or product currently undergoing expert review to determine its eligibility for proresilient classification.
Cellular chronoblocker statuses
Cellular chronoblockers are substances and products that have been shown to reliably increase both lifespan and healthspan.
-
Cellular chronoblocker is a substance or product that has been shown to extend lifespan and healthspan by influencing core biological mechanisms of aging.
-
Candidate into cellular chronoblocker is a substance or product with early evidence suggesting chronoblocking effects, pending further scientific confirmation.
-
Under consideration - a substance or product being reviewed by experts for potential classification as a cellular chronoblocker.
